July 1 (Reuters) - Vertex said on Tuesday that
its next-generation drug, Alyftrek, gained European Commission
approval for the treatment of cystic fibrosis.
CF is an inherited disorder resulting from the absence of a
specific protein, which disrupts the movement of salt and water
in and out of cells in various organs.